Response to: Commentary on “Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study”
Authors: Andreas Reif, A. Elif Anıl Yağcıoğlu, Istvan Bitter et al.
Publication: European Neuropsychopharmacology
Published: Nov 1, 2026
Source: Crossref